善得定治疗急性胰腺炎的体会

Role of Sandostatin in the Treatment of Acute Pancreatitis

作者对比观察了善得定对急性胰腺炎的治疗作用，其剂量为０．１～０．１５ｍｇ，每４～６ｈ一次，皮下注射。在８５例水肿型胰腺炎中，１５例应用善得定治疗，结果显示，善得定治疗组转手术率显著低于非善得定组（Ｐ＜０．０５），未合并感染的１２例坏死性胰腺炎均采取非手术治疗，其中３例应用善得定治疗，其合并症全部消失，明显优于对照组。合并感染的６７例坏死性胰腺炎均予以手术治疗，病情严重的１４例，用善得定治疗，结果显示可减少并发症及其严重度。

The effect of sandostatin on the management of Acute Pancreatitis remains controversial. The aim of this study is to evaluate the valus of sandostatin on the cource of acute pancreatitis basing on the analysis retrospectively of the 155 patients admitted to RuiJin Hospital during recent two years. In these 155 patients ,85 patients were diagnosed as acute edematous pancreatitis (AEP), 12 as acute necrotic pancreatitis (ANP) non-infected and 67 casee as ANP infected. For the patients with AEP, 15 cases the sandostatin was used(SS group) and other 70 cases sendostatin not used (Non-SS group). The result shown that the cure rate and the mean hospitalization time were better in the SS group than in the No-SS group. For the 12 patients with ANP Non- infected, all treated by conservative treatment,sandostatin was used in 3 cases (SS group) and in other 9 cases sandostatin was not used (Non-SS group). There was a higher succes rate of conservative treatment in the SS group than in the Non-SS group. For the 67 patients with ANP infected,all treated operatively,more severe cases were given sandostatin in the regime (SS group) and in other 53 cases sandostatin not (Non-SS geoup). There was lower rate of postoperative complication in the SS group than in the Non-SS group.